Trump signs executive order fast-tracking psychedelic therapy: what it actually does

On Saturday, April 18, 2026, President Donald J. Trump signed an executive order titled *Accelerating Medical Treatments for Serious Mental Illness*. The signing took place in the Oval Office with Health and Human Services Secretary Robert F. Kennedy Jr., CMS Administrator Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell and podcast host Joe Rogan in the room. This is the most substantive federal action on psychedelic medicine in more than 50 years.

It is also a policy document, not a headline. The actual language does specific things, leaves other things alone, and sets up a chain of administrative follow-on actions that will determine whether this changes anything in clinics or not. Here is what it does, in the order that matters to patients.

1. FDA Priority Vouchers for up to 3 psychedelics

The most operationally real change. The order directs the FDA Commissioner to issue National Priority Vouchers (NPVs) to appropriate psychedelic drugs that have already received Breakthrough Therapy designation. NPVs compress the FDA review window from several months to a period of weeks.

Three drugs realistically qualify right now. Lykos Therapeutics' MDMA-assisted therapy for PTSD, which the FDA declined to approve in August 2024 and has since been resubmitted with additional data. Compass Pathways' COMP360 synthetic psilocybin for treatment-resistant depression (Phase 3 readouts are ongoing). And MindMed's MM120 LSD for generalized anxiety disorder.

If the FDA issues vouchers to any of these within the next 90 days, the first FDA-approved non-esketamine psychedelic medicine could land in late 2026 or early 2027. That is significantly faster than the pre-order baseline.

2. Right to Try pathway for ibogaine and other investigational psychedelics

The order explicitly directs the FDA and DEA to establish a pathway for eligible patients to access investigational psychedelic drugs, *including ibogaine compounds*, that are under FDA review and have met basic safety requirements under the Right to Try Act.

Right to Try is not new (signed into law in 2018) but has been used sparingly for psychedelics because ibogaine is Schedule I and DEA has not previously created a companion pathway. This order names ibogaine directly, which is why Joe Rogan's presence at the signing is not ornamental. Rogan has been the single loudest public voice for ibogaine access for US veterans.

Practically: if ibogaine is in an active FDA clinical program (it is - Atai Life Sciences, DemeRx, and others run ibogaine analog trials), an eligible patient could potentially access it outside of a trial under Right to Try. Patient eligibility, sponsor willingness, and DEA coordination still have to be sorted out via follow-on rule-making. That will take weeks, not hours.

3. $50 million in ARPA-H funding (matched with state dollars)

The Secretary of Health and Human Services is directed to allocate $50 million through the Advanced Research Projects for Health (ARPA-H) program to match state-government investments in psychedelic research for populations with serious mental illness.

Oregon, Colorado, Connecticut, New York, California and Texas all have some form of state-level psychedelic research or service-center funding already on the books. A federal dollar-for-dollar match against those budgets is meaningful for the research pipeline but will not fund new clinics directly.

4. VA, HHS, FDA required to coordinate trial access

The Department of Veterans Affairs is already running at least five psychedelic trials across New York, California and Oregon. The order directs HHS and FDA to work with the VA and private sector on expanding those. For the 25% of post-9/11 veterans who carry a PTSD diagnosis, this is the piece with the clearest immediate impact: more open trial slots, in more states, faster.

5. DEA rescheduling review triggered on Phase 3 completion

The Attorney General is directed to initiate a product review for potential rescheduling as soon as a psychedelic completes Phase 3 trials. Under previous practice, rescheduling review did not begin until after FDA approval, creating a months-long gap between approval and legal clinical availability. This preempts that gap.

What this is not

The executive order does not legalize any psychedelic, does not create any new FDA-approved product on its own, and does not change anything you can walk into a clinic tomorrow and receive. Spravato remains the only FDA-approved psychedelic-class medicine. Psilocybin remains legal only at Oregon-licensed service centers and Colorado DORA-licensed healing centers. Ibogaine remains Schedule I outside of research contexts.

It also does not override state law. California, Florida and Texas all retain their current restrictions. States that want to lean in (Oregon, Colorado) will get more federal support; states that do not want to lean in keep their existing framework.

What patients should actually do

If you are in a serious-mental-illness diagnostic category (TRD, PTSD, severe anxiety, opioid use disorder) and you were already considering psychedelic-assisted therapy, the answer this week is identical to last week: work with a licensed prescriber, pursue the in-trial or in-clinic path appropriate to your condition, and do not attempt to self-source any Schedule I substance based on a press release.

If you are a US veteran specifically interested in ibogaine, the realistic near-term paths are: enrollment in an FDA clinical trial (search ClinicalTrials.gov for ibogaine or noribogaine), an international treatment center in Mexico or Costa Rica operating outside US jurisdiction, or waiting 60-90 days for the Right to Try rule-making to surface and see what the eligibility criteria actually are.

Timeline

The order has no specific implementation deadlines. Based on prior FDA voucher program rollouts and DEA rule-making cycles, expect: voucher issuance within 30-90 days, Right to Try rule-making draft within 60-120 days, and first real patient access outside of trials in Q3 or Q4 2026 at the earliest. We will keep this page updated as follow-on actions land.

Sources

The White House, *Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness*, April 18, 2026. NPR, *Trump signs order fast tracking review of psychedelics for mental health disorders*, April 18, 2026. STAT, *How Trump is pushing psychedelics reform through the health agencies*, April 18, 2026. CNBC, *Trump signs order to speed review of psychedelics, including the controversial drug ibogaine*, April 18, 2026. Al Jazeera, *Trump joined by Joe Rogan as he signs order to speed up psychedelic review*, April 18, 2026.